Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Sekhar Surapaneni"'
Autor:
Yanshan Dai, Huijin Dong, Carol Gleason, Johanna Mora, Gerry Kolaitis, Nanda Balasubramanian, Sekhar Surapaneni, Alexander Kozhich, Vibha Jawa
Publikováno v:
The AAPS Journal. 25
Autor:
Surinder Kaur, Stephen C Alley, Matt Szapacs, Amanda Wilson, Eugene Ciccimaro, Dian Su, Neil Henderson, Linzhi Chen, Fabio Garofolo, Shawna Hengel, Wenying Jian, John F Kellie, Anita Lee, John Mehl, Joe Palandra, Haibo Qiu, Natasha Savoie, Diaa Shakleya, Ludovicus Staelens, Hiroshi Sugimoto, Giane Sumner, Jan Welink, Robert Wheller, Y-J Xue, Jianing Zeng, Jinhui Zhang, Huiyu Zhou, Jian Wang, Scott Summerfield, Olga Kavetska, Lieve Dillen, Ragu Ramanathan, Mike Baratta, Arindam Dasgupta, Anna Edmison, Luca Ferrari, Sally Fischer, Daniela Fraier, Sam Haidar, Kathrin Heermeier, Christopher James, Allena Ji, Lina Luo, Gustavo Mendes Lima Santos, Noah Post, Anton I Rosenbaum, Sune Sporring, Sekhar Surapaneni, Stephen Vinter, Katty Wan, Eric Woolf, Seongeun (Julia) Cho, Elham Kossary, Sandra Prior, Mohsen Rajabi Abhari, Catherine Soo, Yow-Ming Wang, Abbas Bandukwala, Elana Cherry, Isabelle Cludts, Soma Ghosh, Shirley Hopper, Akiko Ishii-Watabe, Susan Kirshner, Kevin Maher, Kimberly Maxfield, Joao Pedras-Vasconcelos, Yoshiro Saito, Dean Smith, Therese Solstad, Daniela Verthelyi, Meenu Wadhwa, Leslie Wagner, Günter Waxenecker, Haoheng Yan, Lucia Zhang
Publikováno v:
Bioanalysis. 14:505-580
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on 27 September to 1 October 2021. Even with a last-minute move from in-person to virtual, an overwhelmingly high number of nearly 900 professionals representing ph
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Autor:
Yongjun Xue, Sekhar Surapaneni, Mark Thomas, Gopal Krishna, Leonidas N Carayannopoulos, Simon Zhou, Mary Liu, Jeanelle Kam, Liangang Liu, Ken Ogasawara, Maria Palmisano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:369-377
Fedratinib is an oral and selective Janus kinase 2 inhibitor that is indicated for treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Fedratinib is metabolized by cytochrome P450s (CYPs), primarily CYP3A4. The ob
Publikováno v:
Drug Metabolism and Disposition. 49:601-609
Ozanimod, recently approved for treating relapsing multiple sclerosis, produced a disproportionate, active, MAO B–catalyzed metabolite (CC112273) that showed remarkable interspecies differences and led to challenges in safety testing. This study ex
Autor:
Yizhe Chen, Ken Ogasawara, Rebecca Wood-Horrall, Mark Thomas, Michael Thomas, Bing He, Liangang Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N. Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna
Publikováno v:
Cancer chemotherapy and pharmacology. 90(4)
Purpose Fedratinib is an orally administered Janus kinase (JAK) 2–selective inhibitor for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. In vitro, fedratinib is predominantly metabolized by cyto
Autor:
Surinder, Kaur, Stephen C, Alley, Matt, Szapacs, Amanda, Wilson, Eugene, Ciccimaro, Dian, Su, Neil, Henderson, Linzhi, Chen, Fabio, Garofolo, Shawna, Hengel, Wenying, Jian, John F, Kellie, Anita, Lee, John, Mehl, Joe, Palandra, Haibo, Qiu, Natasha, Savoie, Diaa, Shakleya, Ludovicus, Staelens, Hiroshi, Sugimoto, Giane, Sumner, Jan, Welink, Robert, Wheller, Y-J, Xue, Jianing, Zeng, Jinhui, Zhang, Huiyu, Zhou, Jian, Wang, Scott, Summerfield, Olga, Kavetska, Lieve, Dillen, Ragu, Ramanathan, Mike, Baratta, Arindam, Dasgupta, Anna, Edmison, Luca, Ferrari, Sally, Fischer, Daniela, Fraier, Sam, Haidar, Kathrin, Heermeier, Christopher, James, Allena, Ji, Lina, Luo, Gustavo Mendes, Lima Santos, Noah, Post, Anton I, Rosenbaum, Sune, Sporring, Sekhar, Surapaneni, Stephen, Vinter, Katty, Wan, Eric, Woolf, Seongeun Julia, Cho, Elham, Kossary, Sandra, Prior, Mohsen Rajabi, Abhari, Catherine, Soo, Yow-Ming, Wang, Abbas, Bandukwala, Elana, Cherry, Isabelle, Cludts, Soma, Ghosh, Shirley, Hopper, Akiko, Ishii-Watabe, Susan, Kirshner, Kevin, Maher, Kimberly, Maxfield, Joao, Pedras-Vasconcelos, Yoshiro, Saito, Dean, Smith, Therese, Solstad, Daniela, Verthelyi, Meenu, Wadhwa, Leslie, Wagner, Günter, Waxenecker, Haoheng, Yan, Lucia, Zhang
Publikováno v:
Bioanalysis. 14(9)
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on 27 September to 1 October 2021. Even with a last-minute move from in-person to virtual, an overwhelmingly high number of nearly 900 professionals representing ph
Autor:
Xiaomin Wang, Richard Hargreaves, Julie V. Selkirk, Sekhar Surapaneni, Jennifer Brooks, Yingzhuo Grace Yan, Peijin Zhang, Deepak Dalvie, Gondi Kumar, Maria Palmisano, Jonathan Q. Tran, Usha Yerramilli, April Bai
Publikováno v:
Drug Metabolism and Disposition. 49:405-419
Ozanimod is approved for the treatment of relapsing forms of multiple sclerosis. Absorption, metabolism, and excretion of ozanimod were investigated after a single oral dose of 1.0 mg [14C]ozanimod hydrochloride to six healthy subjects. In vitro expe
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Fedratinib (INREBIC®), a Janus kinase 2 inhibitor, is approved in the United States to treat patients with myelofibrosis. Fedratinib is not only a substrate of cytochrome P450 (CYP) enzymes, but also exhibits complex auto-inhibition, time-de
Autor:
Ken Ogasawara, Christine Xu, Maria Palmisano, Laurence Ridoux, Vanaja Kanamaluru, Nicholas Siebers, Sekhar Surapaneni, Gopal Krishna
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:307-314
Fedratinib is an oral and selective kinase inhibitor with activity against wild type and mutationally activated Janus kinase 2 and FMS-like tyrosine kinase 3, for the treatment of adult patients with intermediate-2 or high-risk primary or secondary m